Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, et al.
…t tuberculosis (MDR-TB) is only 54%, and therefore new drug regimens are urgently needed. In this study, we evaluated the activity of the combination of moxifloxacin and linezolid as a possible new MDR-TB regimen in a murine TB model and the value of the addition of the efflux pu…
Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, et al.
…onclusions: Compared with traditional injectable-containing regimens, an all-oral 6-month levofloxacin, bedaquiline, and linezolid-containing MDR/RR-TB regimen was associated with a significantly improved 24-month WHO-defined treatment outcome (predominantly owing to toxicity-rel…
Lempens P, Decroo T, Aung KJM, Hossain MA, Rigouts L, et al.
Objectives We investigated whether companion drug resistance was associated with adverse outcomes of the shorter multidrug-resistant tuberculosis (MDR-TB) treatment regimen in Bangladesh after adjustment for fluoroquinolone resistance. Methods MDR-TB/rifampicin-resistant tubercul…
Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, et al.
…At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their avail…
Marina Calamelli, Caterina Davoli, Roberta Gerami, Maurizio Gulletta, Sofia Lovatti, et al.
… efficacy. Further evidence is urgently required on shorter regimens such as BPaLM for the treatment of extrapulmonary tuberculosis involving the brain and bones.
E Birmingham, B Remmerie, I Leipoldt, I Eshun-Wilsonova, K Callewaert, et al.
**BACKGROUND:** Multidrug-resistant TB regimens are associated with higher risk of QT prolongation; understanding bedaquiline's (BDQ) role is crucial for safety and management. **METHODS:** We report a pre-specified secondary analysis of data from STREAM Stage 2 (ISRCTN18148631)…
Saiduo Liu, Xinchun Ye, Fang Cheng, Kaijia Wu, Jiandan Yu, et al.
…nvestigated the clinical efficacy of bedaquiline‐containing regimens in the treatment of drug‐resistant pulmonary tuberculosis and the diagnostic value of computed tomography (CT). Methods We retrospectively analyzed the clinical diagnosis, treatment, and CT imaging data of patie…
Kusmiati T, Mertaniasih NM, Putranto JNE, Suprapti B, Luthfah N, et al.
… of rifampicin-resistant (RR-TB) patients receiving shorter regimens. Correlation for all variables was analyzed. Results CRP, IL-1β, and QTc baseline showed significant differences between 45 RR-TB patients on intensive phase and continuation phase with p-value of Conclusion Mox…
Asan Medical Center
The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial. The BPaL (Bedaquiline, Pr…
Ying Zhang, PhD, Wenhong Zhang, PhD,MD
Multidrug resistant tuberculosis (MDR-TB) is difficult to treat and raises a great challenge to TB control program. That pyrazinamide can shorten the course of treatment and facilitate bacilli clearance has been proved recently. In 2011, WHO recommended to use pyrazinamide throug…
Anant Mohan, Anuj Bhatnagar, Tarang Gupta, Sunita Kanswal, Ujjalkumar Subhash Das, et al.
Abstract Patients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated on re-treatment regimen. These patients are known to have adverse outcomes. This study aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcom…
Yuxia Zhang, Yu Xiong, Tingting Chang, Yanming Sun, Zhiyuan Zhao, et al.
…ning contezolid was comparable to the traditional long-term regimens in sputum negative conversion rate after 6 months of treatment, with decreased incidence of adverse reactions. Disclosures All Authors: No reported disclosures
Santosh Mittal, Devinder Kumar Vohra
Background: In an attempt to reduce the length of conventional MDR TB regimen for 18months or more WHO updated its treatment guidelines in May 2016and included a recommendation on the use of Standardised Shorter MDR TB regimen with seven drugs and a treatment duration of 9to 12 m…
Y. I. Feschenko, N.А. Lytvynenko, Н.В. Гранкіна, Maryna Pogrebna, Yu.О. Senko, et al.
OPTIMAL DURATION OF INDIVIDUALIZED REGIMENS OF ANTIMYCOBACTERIAL THERAPY, CONTAINING BEDAQUILINE AND REPURPOSED MEDICINES, FOR PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS INCLUDING Y. I. Feschenko, N. A. Lytvynenko, N. V.Grankina, M. V. Pogrebna, Y. O. Senko, L. M. Protsyk Abs…
Marco Schiuma, Souleymane Hassane Harouna
…anuary 2025. Linezolid, a key component of new therapeutic regimens such as BPaL/BPaL-M, shows high bactericidal activity, although it is associated with serious adverse effects in a high percentage of patients, including myelosuppression, neuropathy and, in some cases, fatal la…
Prashant Yadav, Aditya Kumar Gautam, Ashish Kumar Gupta, Adesh Kumar, Shashank Kumar, et al.
Background: The effectiveness of shorter regimen for the treatment of MDR-TB patients was found in the study done by Damien Foundation in Bangladesh, therefore we planned to study the profile MDR-TB patients who were taking shorter regimen so that various factors can be explored …
Innocent Murhula Kashongwe, Nicole Anshambi, Nadine Maingowa, Murielle Aloni, Michel Kaswa, et al.
Background: Ototoxicity remains one of the major adverse events during multidrug-resistant tuberculosis (MDR-TB) treatment. It is related to the use of aminoglycosides. Bedaquiline offers an opportunity to promote a shorter regimen without aminoglycosides. Methods: This is a retr…
Schwoebel V, Chiang CY, Trébucq A, Piubello A, Aït-Khaled N, et al.
…osis (MDR-TB) treatment outcomes apply to shorter treatment regimens in low- and middle-income countries and to propose modified criteria. METHODS Criteria for 'failure' and 'cure' outcomes were assessed using data on 1006 patients enrolled in an observational study on the standa…
Arias L, Otwombe K, Waja Z, Tukvadze N, Korinteli T, et al.
… TB. As each TB case is different, individualized treatment regimens should be applied to obtain better outcomes. In this scenario, novel therapeutic approaches are urgently needed to (1) improve outcomes and (2) shorten treatment duration, and host-directed therapies (HDT) might…
Umar M, Basit A, Ali S, Iqbal Z, Jan F
Background The currently recommended treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are complex, costly, prolonged (lasting at least 20 months), and often poorly tolerated. The objective of this study was to evaluate the effectiveness of the shorter treatment re…
Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, et al.
…ation called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and effectiveness of three 9-month all-oral regimens containing bedaquiline (Bdq), linezolid (Lzd), and levofloxacin (Lfx) and r…
Nyang'wa BT, Kloprogge F, Moore DAJ, Bustinduy A, Motta I, et al.
…ith little over 50% of patients successfully treated. Novel regimens like the ones being studied in the TB-PRACTECAL trial are urgently needed. Understanding anti-TB drug exposures could explain the success or failure of these trial regimens. We aim to study the relationship betw…
Gao J, Gao M, Du J, Pang Y, Mao G, et al.
…uction The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has significantly impeded TB control efforts in China. Methods This phase 4, randomized, open-label, controlled, non-inferio…
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.
…ble, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). Participants were randomly assigned (with the u…
А. V. Kukurika, А Б Перегудова, L. E. Parolina, T. V. Pyanzova, E. O. Bryukhacheva, et al.
…e: to study the effectiveness and safety of new chemotherapy regimens at the end of the intensive phase in the patients suffering from multiple drug resistant tuberculosis (MDR TB), concurrent HIV infection (HIV), and chronic hepatitis C (HCV). Subjects and Methods. The effectivenes…